Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $1,300.00 and $805.00 suggesting an average Analsyt target price of $1,167.55. Given that the stocks previous close was at $1,199.29 this is indicating there is a potential downside of -2.6%. There is a 50 day moving average of $1,100.70 and the 200 moving average now moves to $970.70. The market capitalization for the company is 129.96B. The stock price is currently at: $1,178.93 USD
The potential market cap would be $126,519,894,431 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 31.25, revenue per share of $125.83 and a 7.61% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
